ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 106 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is 0.08 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $833,590 | -33.9% | 121,692 | 0.0% | 0.56% | -34.6% |
Q2 2023 | $1,261,946 | +28.0% | 121,692 | -0.1% | 0.86% | +17.8% |
Q1 2023 | $985,686 | -75.5% | 121,840 | -52.2% | 0.73% | -70.6% |
Q4 2022 | $4,016,250 | +58.6% | 255,000 | +58.5% | 2.47% | +126.8% |
Q3 2022 | $2,532,000 | -5.9% | 160,835 | -16.6% | 1.09% | -27.3% |
Q2 2022 | $2,692,000 | -28.2% | 192,835 | -11.4% | 1.50% | -14.4% |
Q1 2022 | $3,751,000 | +163.2% | 217,600 | +122.0% | 1.75% | +192.7% |
Q4 2021 | $1,425,000 | -43.8% | 98,000 | -30.4% | 0.60% | -33.0% |
Q3 2021 | $2,535,000 | -17.5% | 140,839 | -19.5% | 0.89% | -27.2% |
Q2 2021 | $3,073,000 | -61.6% | 175,000 | -44.9% | 1.23% | -57.5% |
Q1 2021 | $8,007,000 | +251.0% | 317,730 | +243.5% | 2.89% | +569.8% |
Q4 2017 | $2,281,000 | -6.6% | 92,500 | +2.8% | 0.43% | -36.9% |
Q2 2017 | $2,441,000 | -59.1% | 90,000 | -55.0% | 0.68% | -51.7% |
Q1 2017 | $5,964,000 | -41.0% | 200,000 | -46.3% | 1.41% | -62.4% |
Q4 2016 | $10,117,000 | – | 372,753 | – | 3.76% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |